Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14465008 | 1.00 | AHR (0.48) | AHRCYP1A2ALOX5PTGS1PTGS2 | |
| SCHEMBL10131184 | 1.00 | AHR (0.48) | AHRCYP1A2ALOX5PTGS1PTGS2 | |
| SCHEMBL30953547 | 0.83 | AHR (0.43) | AHRCYP1A2ALOX5PTGS1PTGS2 | |
| SCHEMBL12784385 | 0.82 | ADRB2 (0.46) | AHRCYP1A2ALOX5PTGS1PTGS2 | |
| SCHEMBL2080028 | 0.82 | ADRB2 (0.46) | AHRCYP1A2ALOX5PTGS1PTGS2 | |
| SCHEMBL12784436 | 0.82 | ADRB2 (0.46) | AHRCYP1A2ALOX5PTGS1PTGS2 | |
| SCHEMBL2077776 | 0.82 | ADRB2 (0.46) | AHRCYP1A2ALOX5PTGS1PTGS2 | |
| SCHEMBL10365515 | 0.82 | AHR (0.45) | AHRCYP1A2ALOX5PTGS1PTGS2 | |
| SCHEMBL2077774 | 0.82 | ADRB2 (0.46) | AHRCYP1A2ALOX5PTGS1PTGS2 | |
| SCHEMBL23623944 | 0.81 | TYR (0.54) | PTGS1PTGS2NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| US-20220024906-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2022-01-27 | — | — | US | disclosed |
| US-20210338610-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | HEPANOVA, INC. | 2021-11-04 | — | — | US | disclosed |
| US-11090325-B2 | Compositions for treating ebola virus infection | REDHILL BIOPHARMA LTD. (IL) | 2021-08-17 | — | — | US | disclosed |
| US-11000491-B2 | Amino-aryl-benzamide compounds and methods of use thereof | HEPANOVA, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3239139-B1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | NINGBO COMBIREG PHARMACEUTICAL TECH CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | REDHILL BIOPHARMA LTD (IL) | 2020-05-21 | — | — | US | disclosed |
| US-10463654-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2019-11-05 | — | — | US | disclosed |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD (IL) | 2018-05-10 | — | — | US | disclosed |
| US-9844540-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2017-12-19 | — | — | US | disclosed |
| US-8633205-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130184240-A1 | HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | SHIONOGI & CO., LTD. (JP) | 2013-07-18 | — | — | US | disclosed |
| US-8283368-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283368-B2 | Selective ligands for the dopamine 3 (D3) receptor and methods of using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | BAYER CROPSCIENCE AG (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-28 | — | — | US | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-01-04 | — | — | US | disclosed |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024906-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | AHR 2635/4885CYP1A2 4719/4885ALOX5 2740/4885 |
| US-20130184240-A1 | HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | PRKAA1, PRKAA2, PRKAG1 | AHR 1693/4885CYP1A2 2726/4885ALOX5 4503/4885 |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | PRKDC, MAP3K20, MAP3K5 | AHR 4279/4885CYP1A2 3753/4885ALOX5 3754/4885 |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | TPMT, KRAS, ACE | AHR 930/4885CYP1A2 437/4885ALOX5 4276/4885 |
| US-20200155585-A1 | COMPOSITIONS FOR TREATING EBOLA VIRUS INFECTION | NEFM, EIF2AK2, IRF3 | AHR 4876/4885CYP1A2 4500/4885ALOX5 1356/4885 |
| US-20120157306-A1 | Substituted Fused Pyrimidinones and Dihydropyrimidinones | DHPS, FDPS, DPYD | AHR 1551/4885CYP1A2 862/4885ALOX5 3707/4885 |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | AHR 4396/4885CYP1A2 3277/4885ALOX5 3874/4885 |
| US-20110184033-A1 | Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same | DRD3, HTR3C, HTR3A | AHR 312/4885CYP1A2 1924/4885ALOX5 2826/4885 |
| US-11000491-B2 | Amino-aryl-benzamide compounds and methods of use thereof | AADAC, GOT2, ABAT | AHR 38/4885CYP1A2 272/4885ALOX5 502/4885 |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | AHR 2449/4885CYP1A2 104/4885ALOX5 736/4885 |
| US-10463654-B2 | Combination therapies for treating cancer | TPMT, KRAS, ACE | AHR 930/4885CYP1A2 437/4885ALOX5 4276/4885 |
| US-20210338610-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, GOT2, ABAT | AHR 38/4885CYP1A2 272/4885ALOX5 502/4885 |
| US-11090325-B2 | Compositions for treating ebola virus infection | NEFM, EIF2AK2, IRF3 | AHR 4876/4885CYP1A2 4500/4885ALOX5 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.